Cardiomyopathies: The Role of Non-Coding RNAs

Overview

Journal Noncoding RNA

Date 2024 Oct 25

PMID 39449507

Authors

Nicole Carabetta

Chiara Siracusa

Isabella Leo

Giuseppe Panuccio

Antonio Strangio

Jolanda Sabatino

Daniele Torella

Salvatore De Rosa

Affiliations

Soon will be listed here.

Abstract

Cardiomyopathies are the structural and functional disorders of the myocardium. Etiopathogenesis is complex and involves an interplay of genetic, environmental, and lifestyle factors eventually leading to myocardial abnormalities. It is known that non-coding (Nc) RNAs, including micro (mi)-RNAs and long non-coding (lnc) RNAs, play a crucial role in regulating gene expression. Several studies have explored the role of miRNAs in the development of various pathologies, including heart diseases. In this review, we analyzed various patterns of ncRNAs expressed in the most common cardiomyopathies: dilated cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. Understanding the role of different ncRNAs implicated in cardiomyopathic processes may contribute to the identification of potential therapeutic targets and novel risk stratification models based on gene expression. The analysis of ncRNAs may also be helpful to unveil the molecular mechanisms subtended to these diseases.

References

Wu T, Chen Y, Du Y, Tao J, Zhou Z, Yang Z . Serum Exosomal MiR-92b-5p as a Potential Biomarker for Acute Heart Failure Caused by Dilated Cardiomyopathy. Cell Physiol Biochem. 2018; 46(5):1939-1950. DOI: 10.1159/000489383. View

Besler C, Urban D, Watzka S, Lang D, Rommel K, Kandolf R . Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail. 2016; 18(12):1442-1451. DOI: 10.1002/ejhf.579. View

Zhang C, Xiong Y, Zeng L, Peng Z, Liu Z, Zhan H . The Role of Non-coding RNAs in Viral Myocarditis. Front Cell Infect Microbiol. 2020; 10:312. PMC: 7343704. DOI: 10.3389/fcimb.2020.00312. View

Su M, Wang J, Wang C, Wang X, Dong W, Qiu W . MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ. 2014; 22(6):986-99. PMC: 4423182. DOI: 10.1038/cdd.2014.187. View

Teekakirikul P, Kelly M, Rehm H, Lakdawala N, Funke B . Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013; 15(2):158-70. DOI: 10.1016/j.jmoldx.2012.09.002. View

Li F, Zhang K, Xu T, Du W, Yu B, Liu Y . Exosomal microRNA-29a mediates cardiac dysfunction and mitochondrial inactivity in obesity-related cardiomyopathy. Endocrine. 2018; 63(3):480-488. DOI: 10.1007/s12020-018-1753-7. View

Latronico M, Catalucci D, Condorelli G . MicroRNA and cardiac pathologies. Physiol Genomics. 2008; 34(3):239-42. DOI: 10.1152/physiolgenomics.90254.2008. View

Wang H, Chen F, Tong J, Li Y, Cai J, Wang Y . Circulating microRNAs as novel biomarkers for dilated cardiomyopathy. Cardiol J. 2016; 24(1):65-73. DOI: 10.5603/CJ.a2016.0097. View

Gabriel A, Costa M, Caldeira D, Placido R, Rigueira J, Carrilho-Ferreira P . Role of myocardial microRNAs in the long-term ventricular remodelling of patients with aortic stenosis. Eur Heart J Open. 2024; 4(4):oeae060. PMC: 11311707. DOI: 10.1093/ehjopen/oeae060. View

10.

Huang C, Wang R, Lu J, He Y, Wu Y, Ma W . MicroRNA-338-3p as a therapeutic target in cardiac fibrosis through FGFR2 suppression. J Clin Lab Anal. 2022; 36(8):e24584. PMC: 9396162. DOI: 10.1002/jcla.24584. View

11.

Fu X, Mishra R, Chen L, Arfat M, Sharma S, Kingsbury T . Exosomes mediated fibrogenesis in dilated cardiomyopathy through a MicroRNA pathway. iScience. 2023; 26(2):105963. PMC: 9932122. DOI: 10.1016/j.isci.2023.105963. View

12.

Onrat S, Onrat E, Ercan Onay E, Yalim Z, Avsar A . The Genetic Determination of the Differentiation Between Ischemic Dilated Cardiomyopathy and Idiopathic Dilated Cardiomyopathy. Genet Test Mol Biomarkers. 2018; 22(11):644-651. DOI: 10.1089/gtmb.2018.0188. View

13.

Clippinger S, Cloonan P, Greenberg L, Ernst M, Stump W, Greenberg M . Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2019; 116(36):17831-17840. PMC: 6731759. DOI: 10.1073/pnas.1910962116. View

14.

Fan K, Zhang H, Shen J, Zhang Q, Li X . Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 2013; 65(1):12-6. PMC: 3860780. DOI: 10.1016/j.ihj.2012.12.022. View

15.

Altesha M, Ni T, Khan A, Liu K, Zheng X . Circular RNA in cardiovascular disease. J Cell Physiol. 2018; 234(5):5588-5600. DOI: 10.1002/jcp.27384. View

16.

Glavaski M, Velicki L, Vucinic N . Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers. Medicina (Kaunas). 2023; 59(8). PMC: 10456451. DOI: 10.3390/medicina59081424. View

17.

Gupta M, Sahu A, Sun Y, Mohan M, Kumar A, Zalavadia A . Cardiac expression of microRNA-7 is associated with adverse cardiac remodeling. Sci Rep. 2021; 11(1):22018. PMC: 8581024. DOI: 10.1038/s41598-021-00778-6. View

18.

Beg F, Wang R, Saeed Z, Devaraj S, Masoor K, Nakshatri H . Inflammation-associated microRNA changes in circulating exosomes of heart failure patients. BMC Res Notes. 2017; 10(1):751. PMC: 5735935. DOI: 10.1186/s13104-017-3090-y. View

19.

Zalivina I, Barwari T, Yin X, Langley S, Barallobre-Barreiro J, Wakimoto H . Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling. J Mol Cell Cardiol Plus. 2023; 6():100056. PMC: 10739604. DOI: 10.1016/j.jmccpl.2023.100056. View

20.

Fatkin D, Huttner I, Kovacic J, Seidman J, Seidman C . Precision Medicine in the Management of Dilated Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 74(23):2921-2938. DOI: 10.1016/j.jacc.2019.10.011. View